Sequent Asset Management, LLC Abb Vie Inc. Transaction History

Sequent Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 10, 2023	SELL	$144.61 - $166.54 $13,593 - $15,654	-94 Reduced 4.07%	2,217 $353,000
Q2 2022 Jul 07, 2022	BUY	$137.62 - $174.96 $6,192 - $7,873	45 Added 1.99%	2,311 $354,000
Q1 2022 Apr 18, 2022	SELL	$131.98 - $163.75 $17,289 - $21,451	-131 Reduced 5.47%	2,266 $368,000
Q4 2021 Jan 21, 2022	BUY	$107.43 - $135.93 $257,509 - $325,824	2,397 New	2,397 $325,000
Q4 2020 Jan 19, 2021	SELL	$80.49 - $108.67 $517,148 - $698,204	-6,425 Closed	0 $0
Q2 2019 Jul 31, 2019	SELL	$65.7 - $83.98 $73,912 - $94,477	-1,125 Reduced 14.9%	6,425 $467,000
Q3 2017 Oct 26, 2017	BUY	$69.85 - $89.22 $527,367 - $673,611	7,550	7,550 $671,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Sequent Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sequent Asset Management, LLC with notifications on news.